Publication
The Use of Glucagon-Like Peptide 1 Agonists Among Non-Diabetics: Evidence From Medicare Part D
A study of Medicare Part D beneficiaries found that nearly 1 in 7 new users of diabetes-indicated GLP-1 medications in early 2023 had no evidence of diabetes, up from 1.3% in 2019. The findings highlight the budgetary implications of off-label GLP-1 prescribing as policymakers consider expanding Medicare coverage for weight management.